Malaysia
Key Insights
- 1
No psychedelics are legally approved for routine patient use in Malaysia; the only relevant pathway visible is regulated esketamine access, not classic psychedelic therapy.
- 2
Blossom’s database shows 5 Malaysia trials, 0 active, 0 research organisations, and compounds limited to esketamine and placebo.
- 3
Malaysia’s standout marker is not a psilocybin milestone but a clinically relevant esketamine footprint, including 19 Malaysian patients in the Asian SUSTAIN-2 subgroup.
- 4
Momentum is thin: the current signal is regulatory and protocol-level rather than pipeline depth, with Malaysia’s 2025 psychiatric pharmacy protocol and NPRA esketamine data-exclusivity record the key watchpoints.
Reimbursed Care Access
Malaysia maintains a restrictive national framework for classical and novel psychedelics: most serotonergic/entheogenic compounds (psilocybin, MDMA, DMT, mescaline, 2C-X, 5‑MeO‑DMT, ibogaine, ayahuasca) are treated as controlled/illegal under national drug control policy with no authorized medical use outside approved research. Esketamine (SPRAVATO) is registered in Malaysia and is available through regulated medical channels; racemic/clinical ketamine is a controlled medicine used in clinical settings (largely as an anaesthetic and off‑label in individual private practices) but does not have broad public reimbursement for psychedelic/psychiatric indications.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Malaysia.